New hepatitis C therapies: The toolbox, strategies, and challenges

Gastroenterology

Volumn 146, Issue 5, 2014, Pages 1176-1192

  Pawlotsky, Jean Michel ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

Author keywords

Daclatasvir; Direct Acting Antivirals; Interferon Free Regimens; Keywords; Simeprevir; Sofosbuvir

Indexed keywords

ABT 072; ABT 450; ACH 2928; ACH 3102; ALISPORIVIR; ANTIVIRUS AGENT; ASUNAPREVIR; BMS 791325; BMS 824393; BOCEPREVIR; DACLATASVIR; DANOPREVIR; DASABUVIR; FALDAPREVIR; GS 5816; GS 9669; GSK 2336805; LEDIPASVIR; LOMIBUVIR; MERICITABINE; MIK 8742; MIRAVIRSEN; MK 8742; NECEPREVIR; OMBITASVIR; PEGINTERFERON ALPHA; PPI 461; PPI 668; RIBAVIRIN; RITONAVIR; SAMATASVIR; SCY 635; SETROBUVIR; SIMEPREVIR; SOFOSBUVIR; SOVAPREVIR; TELAPREVIR; TMC 647055; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANIPREVIR; VEDROPREVIR; VX 135;

ANTIVIRAL THERAPY; DRUG TREATMENT FAILURE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETREATMENT; REVIEW; VIRUS RESISTANCE;

DACLATASVIR; DIRECT-ACTING ANTIVIRALS; INTERFERON-FREE REGIMENS; SIMEPREVIR; SOFOSBUVIR;

ANTIVIRAL AGENTS; DEVELOPING COUNTRIES; DRUG COSTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HEPACIVIRUS; HEPATITIS C; HUMANS; PATIENT SELECTION; PHENOTYPE; PREVALENCE; TREATMENT OUTCOME; WORLD HEALTH;

EID: 84898990930     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.03.003     Document Type: Review

References (92)

1. B.D. Lindenbach Virion assembly and release Curr Top Microbiol Immunol 369 2013 199 218
2. V. Lohmann Hepatitis C virus RNA replication Curr Top Microbiol Immunol 369 2013 167 198
3. M. Niepmann Hepatitis C virus RNA translation Curr Top Microbiol Immunol 369 2013 143 166
4. M.B. Zeisel, D.J. Felmlee, and T.F. Baumert Hepatitis C virus entry Curr Top Microbiol Immunol 369 2013 87 112
5. J.M. Pawlotsky The science of direct-acting antiviral and host-targeted agent therapy Antiviral Ther 17 2012 1109 1117
6. D.B. Smith, J. Bukh, and C. Kuiken et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource Hepatology 59 2014 318 327
7. J.M. Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 2011 1742 1751
8. B.R. Bacon, S.C. Gordon, and E. Lawitz et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
9. I.M. Jacobson, J.G. McHutchison, and G. Dusheiko et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
10. F. Poordad, J. McCone Jr., and B.R. Bacon et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
11. S. Zeuzem, P. Andreone, and S. Pol et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
12. A. Rosenquist, B. Samuelsson, and P.O. Johansson et al. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor J Med Chem 57 2014 1673 1693
13. M. Llinas-Brunet, M.D. Bailey, and N. Goudreau et al. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335) J Med Chem 53 2010 6466 6476
14. P.W. White, M. Llinas-Brunet, and M. Amad et al. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease Antimicrob Agents Chemother 54 2010 4611 4618
15. F. McPhee, A.K. Sheaffer, and J. Friborg et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032) Antimicrob Agents Chemother 56 2012 5387 5396
16. Y. Jiang, S.W. Andrews, and K.R. Condroski et al. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease J Med Chem 57 2014 1753 1769
17. J.A. McCauley, C.J. McIntyre, and M.T. Rudd et al. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4A protease inhibitor J Med Chem 53 2010 2443 2463
18. X.C. Sheng, T. Appleby, and T. Butler et al. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease Bioorg Med Chem Lett 22 2012 2629 2634
19. H. Yang, M. Robinson, and A.C. Corsa et al. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451 Antimicrob Agents Chemother 58 2014 647 653
20. V. Summa, S.W. Ludmerer, and J.A. McCauley et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4A protease with broad activity across genotypes and resistant variants Antimicrob Agents Chemother 56 2012 4161 4167
21. F. Lahser, R. Liu, and K. Bystol et al. A combination containing MK-5172 (HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in HCV replicons Hepatology 56 2012 236A
22. M.J. Huang, S. Podos, and D. Patel et al. ACH-2684: HCV NS3 protease inhibitor with potent activity against multiple genotypes and known resistant variants Hepatology 52 2010 1204A
23. J. Chow, Y. Liu, and K. Comstock et al. Isolation and identification of ester impurities in RG7128, an HCV polymerase inhibitor J Pharm Biomed Anal 53 2010 710 716
24. M.J. Sofia, D. Bao, and W. Chang et al. Discovery of a beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus J Med Chem 53 2010 7202 7218
25. R. Haudecoeur, M. Peuchmaur, and A. Ahmed-Belkacem et al. Structure-activity relationships in the development of allosteric hepatitis C virus RNA-dependent RNA polymerase inhibitors: ten years of research Med Res Rev 33 2013 934 984
26. R.G. Gentles, M. Ding, and J.A. Bender et al. Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase J Med Chem 57 2014 1855 1879
27. M.D. Cummings, T.I. Lin, and L. Hu et al. Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase J Med Chem 57 2014 1880 1892
28. G. Yi, J. Deval, and B. Fan et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir Antimicrob Agents Chemother 56 2012 830 837
29. S.E. Lazerwith, W. Lew, and J. Zhang et al. Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infection J Med Chem 57 2014 1893 1901
30. J.M. Pawlotsky NS5A inhibitors in the treatment of hepatitis C J Hepatol 59 2013 375 382
31. J. Guedj, H. Dahari, and L. Rong et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Proc Natl Acad Sci U S A 110 2013 3991 3996
32. D.R. McGivern, T. Masaki, and L. Ping et al. Kinetic analyses of antiviral suppression by NS5A inhibitors reveal early and potent inhibition of viral assembly and release of infectious virus Hepatology 58 Suppl 1 2013 246A
33. M. Gao, R.E. Nettles, and M. Belema et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
34. J.O. Link, J.G. Taylor, and L. Xu et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection J Med Chem 57 2014 2033 2046
35. D.A. Degoey, J.T. Randolph, and D. Liu et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A J Med Chem 57 2014 2047 2057
36. R. Colonno, N. Huang, and Q. Huang et al. Characterization and identification of PPI-437, PPI-668 and PPI-833 as potent and selective HCV NS5A inhibitors with activity against all HCV genotypes J Hepatol 54 2011 S474
37. M. Huang, G. Yang, and D. Patel et al. ACH-2928: a novel highly potent HCV NS5A inhibitor with favorable preclinical characteristics J Hepatol 54 2011 S479
38. J. Walker, R. Crosby, and A. Wang et al. Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A Antimicrob Agents Chemother 58 2014 38 47
39. C.A. Coburn, P.T. Meinke, and W. Chang et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity ChemMedChem 8 2013 1930 1940
40. G. Yang, J. Wiles, and D. Patel et al. Preclinical characteristics of ACH-3102: a novel HCV NS5A inhibitor with improved potency against genotype 1a virus and variants resistant to first-generation of NS5A inhibitors J Hepatol 56 2012 S330
41. G. Cheng, M. Yu, and B. Peng et al. GS-5816, a second-generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier J Hepatol 58 2013 S484 S485
42. L. Coelmont, S. Kaptein, and J. Paeshuyse et al. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors Antimicrob Agents Chemother 53 2009 967 976
43. S. Hopkins, B. Scorneaux, and Z.H. Huang et al. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro Antimicrob Agents Chemother 54 2010 660 672
44. H.L. Janssen, H.W. Reesink, and E.J. Lawitz et al. Treatment of HCV infection by targeting microRNA N Engl J Med 368 2013 1685 1694
45. R.E. Lanford, E.S. Hildebrandt-Eriksen, and A. Petri et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection Science 327 2010 198 201
46. W.C. Tsai, S.D. Hsu, and C.S. Hsu et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis J Clin Invest 122 2012 2884 2897
47. I. Jacobson, G.J. Dore, and G.R. Foster et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a phase III trial J Hepatol 58 2013 S574
48. M. Manns, P. Marcellin, and F. Poordad et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial J Hepatol 58 2013 S568
49. E. Lawitz, X. Forns, and S. Zeuzem et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a phase III trial Gastroenterology 144 2013 S151
50. D.M. Jensen, T. Asselah, and D.T. Dieterich et al. A pooled analysis of two randomized, double-blind placebo-controlled phase III trials (STARTVerso 1 & 2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic hepatitis C genotype-1 infection Hepatology 58 Suppl 1 2013 734A 735A
51. I.M. Jacobson, T. Asselah, and P. Ferenci et al. STARTVerso3: a randomized, double-blind, placebo-controlled phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection Hepatology 58 Suppl 1 2013 742A
52. J.K. Rockstroh, M. Nelson, and V. Soriano et al. STARTVerso 4 phase III trial of faldaprevir plus peginterferon alfa-2a and ribavirin (PR) in patients with HIV and HCV genotype 1 coinfection: end-of-treatment response Hepatology 58 Suppl 1 2013 741A
53. J.P. Bronowicki, V. Ratziu, and A. Gadano et al. Asunaprevir with peginterferon-alfa and ribavirin in treatment-naïve patients with genotype-1 or -4 chronic hepatitis C: SVR24 results from a randomized phase 2b study (AI447016) J Hepatol 58 2013 S571 S572
54. P. Marcellin, C. Cooper, and L. Balart et al. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection Gastroenterology 145 2013 790 800
55. E.J. Gane, R. Rouzier, and A. Wiercinska-Drapalo et al. Efficacy and safety of danoprevir/ritonavir plus peginterferon alfa-2a/ribavirin in HCV genotype 1 prior null responders Antimicrob Agents Chemother 58 2014 1136 1145
56. E. Lawitz, M. Rodriguez-Torres, and A. Stoehr et al. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment J Hepatol 59 2013 11 17
57. M. Rodriguez-Torres, A. Stoehr, and E.J. Gane et al. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis Clin Gastroenterol Hepatol 2014 Oct 10 Epub ahead of print
58. C. Hezode, G.M. Hirschfield, and W. Ghesquiere et al. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV genotype 1 or 4 subjects: phase 2b COMMAND-1 SVR12 results Hepatology 56 Suppl 1 2012 553A 554A
59. G.J. Dore, E. Lawitz, and C. Hezode et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 study J Hepatol 58 2013 S570 S571
60. E. Lawitz, A. Mangia, and D. Wyles et al. Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
61. E. Lawitz, F. Poordad, and D.M. Brainard et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study Hepatology 58 Suppl 1 2013 1380A
62. M. Manns, J.M. Vierling, and B.R. Bacon et al. High sustained viral response at 12- and 24-week follow-up of MK-5172 with pegylated interferon alfa-2b and ribavirin (PR) in HCV genotype 1 treatment-naïve non-cirrhotic patients J Hepatol 58 2013 S30
63. A.S. Lok, D.F. Gardiner, and C. Hezode et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders J Hepatol 60 2014 490 499
64. J.J. Feld, I.M. Jacobson, and D.M. Jensen et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) +/- peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study Hepatology 56 2012 231A 232A
65. E.J. Gane, C.A. Stedman, and R.H. Hyland et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N Engl J Med 368 2013 34 44
66. A. Osinusi, E.G. Meissner, and Y.J. Lee et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial JAMA 310 2013 804 811
67. M. Sulkowski, M. Rodriguez-Torres, and J.P. Lalezari et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1) Hepatology 58 Suppl 1 2013 313A
68. P.J. Ruane, D. Ain, and J. Riad et al. Sofosbuvir plus ribavirin in the treatment of chronic HCV genotype 4 infection in patients of Egyptian ancestry Hepatology 58 Suppl 1 2013 736A
69. M.P. Curry, X. Forns, and R.T. Chung et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation Hepatology 58 Suppl 1 2013 314A
70. I.M. Jacobson, S.C. Gordon, and K.V. Kowdley et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
71. S. Zeuzem, G. Dusheiko, and R. Salupere et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial Hepatology 58 Suppl 1 2013 733A
72. Gilead announces SVR12 rates from three phase 3 studies evaluating a once daily fixed dose combination of sofosbuvir and ledipasvir for genotype 1 hepatitis C patients. Available: http://www.gilead.com/news/press-releases/2013/ 12/gilead-announces-svr12-rates-from-three-phase-3-studies-evaluating-a- oncedaily-fixeddose-combination-of-sofosbuvir-and-ledipasvir-for-genotype-1- hepatitis-c-patients?mode=print. Accessed, December 18, 2013.
73. I. Jacobson, R.H. Ghalib, and M. Rodriguez-Torres et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study Hepatology 58 Suppl 1 2013 1379A
74. M.S. Sulkowski, D.F. Gardiner, and M. Rodriguez-Torres et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
75. R.J. Fontana, E.A. Hughes, and M. Bifano et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C Am J Transplant 13 2013 1601 1605
76. K. Chayama, Y. Suzuki, and K. Ikeda et al. All-oral combination of daclatasvir plus asunaprevir in interferon ineligible naive/intolerant and nonresponder Japanese patients chronically infected with HCV genotype 1b: results from a phase 3 trial Hepatology 58 Suppl 1 2013 313A
77. S. Zeuzem, V. Soriano, and T. Asselah et al. Faldaprevir and deleobuvir for HCV genotype 1 infection N Engl J Med 369 2013 630 639
78. J.F. Dufour, M. Buti, and V. Soriano et al. Interferon-free treatment with faldaprevir, deleobuvir (BI 207127) and ribavirin in SOUND-C3: 95% SVR12 in HCV-GT1b Hepatology 58 Suppl 1 2013 744A
79. E. Lawitz, C. Hezode, and P. Varunok et al. Interferon- and ribavirin-free regimen of ABT-450/r + ABT-267 in HCV genotype 1b-infected treatment-naïve patients and prior null responders Hepatology 58 Suppl 1 2013 244A
80. Abbvie releases first of six Phase III results from investigational all-oral interferon-free 12-week regimen showing 96 percent SVR12 in genotype 1 hepatitis C patients new to therapy. Available: http://abbvie.mediaroom.com/ 2013-11-18-AbbVie-Releases-First-of-Six-Phase-III-Results-from-Investigational- All-Oral-Interferon-Free-12-week-Regimen-Showing-96-Percent-SVR12-in-Genotype-1- Hepatitis-C-Patients-New-to-Therapy. Accessed, November 18, 2013.
81. Abbvie demonstrates 96 percent SVR12 in its Phase III study of treatment-experienced patients with genotype 1 hepatitis C. Available: http://abbvie.mediaroom.com/2013-12-10-AbbVie-Demonstrates-96-percent-SVR-12-in- its-Phase-III-Study-of-Treatment-Experienced-Patients-with-Genotype-1-Hepatitis- C. Accessed, December 10, 2013.
82. Abbvie completes largest Phase III program of an all-oral interferon-free therapy for the treatment of hepatitis C genotype 1. Available: http://abbvie.mediaroom.com/2014-01-31-AbbVie-Completes-Largest-Phase-III- Program-of-an-All-Oral-Interferon-Free-Therapy-for-the-Treatment-of-Hepatitis-C- Genotype-1. Accessed, January 31, 2014.
83. G.T. Everson, K.D. Sims, and M. Rodriguez-Torres et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection Gastroenterology 146 2014 420 429
84. E. Lawitz, J.M. Vierling, and A. Murillo et al. High efficacy and safety of the all-oral combination regimen, MK-5172/MK-8742 +/- RBV for 12 weeks in HCV genotype 1 infected patients: the C-WORTHY study Hepatology 58 Suppl 1 2013 244A
85. Highlights of prescribing information. Available: http://www.accessdata. fda.gov/drugsatfda-docs/label/2013/205123s001lbl.pdf.
86. Available: http://www.gilead.com/∼/media/Files/pdfs/medicines/liver- disease/sovaldi/sovaldi-pi.pdf.
87. European Commission grants marketing authorization for Gilead's Sovaldi (sofosbuvir) for the treatment of chronic hepatitis C virus infection. Available: http://www.gilead.com/news/press-releases/2014/1/european-commission- grants-marketing-authorization-for-gileads-sovaldi-sofosbuvir-for-the-treatment- of-chronic-hepatitis-c-infection. Accessed, January 17, 2014.
88. C. Hezode, H. Fontaine, and C. Dorival et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890 J Hepatol 59 2013 434 441
89. J.C. Sullivan, S. De Meyer, and D.J. Bartels et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials Clin Infect Dis 57 2013 221 229
90. R.J. Barnard, J.A. Howe, and R.A. Ogert et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies Virology 444 2013 329 336
91. F. McPhee, D. Hernandez, and F. Yu et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir Hepatology 58 2013 902 911
92. C. Wang, J.H. Sun, and D.R. O'Boyle 2nd et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir Antimicrob Agents Chemother 57 2013 2054 2065